Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies

NCT00904787 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
27
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

CASI pharmaceuticals, Inc.